Tuberculosis (TB) Therapeutics Market
Global Tuberculosis (TB) Therapeutics Market Size, Share & Trends Analysis Report by Disease Type (Active TB and Latent TB), by Therapy (First-Line Therapy and Second-Line Therapy), and Forecast 2019-2025 Update Available - Forecast 2024-2030
Global tuberculosis (TB) therapeutics market is projected to grow at a CAGR of over 4% during the forecast period. TB is one of the top 10 causes of global fatalities as it affects the lungs and causes life-threatening conditions in the human body. The primary factors that drive the growth of the market include the increased incidences of TB among the peoples, development of various drugs, along with government initiatives for promoting education concerning TB among the population. Further, increasing collaboration between academic and private players for novel drug development, and rising incidence of MDR and XDR cases in developing countries, are fuelling the growth of the market.
However, certain factors such as lack of awareness about the disease diagnosis and treatment methods in various developing and under-developed countries such as Africa have been limiting the growth of the market. Moreover, increasing R&D activities for further advanced tuberculosis diagnostics will be the major opportunity for this market. Considering the rising drug-resistant infections, R&D for new vaccines and faster-acting drugs are on the rise, which drives the market during the forecast period.
Segmental Outlook
The global TB therapeutics market is segmented on the basis of disease type and drugs. Based on the disease type, the market is sectioned as active TB and latent TB. Based on the therapy, the market is bifurcated into first-line therapy and second-line therapy. First-line therapy includes drugs such as isoniazid, streptomycin, Rifampin, pyrazinamide, and ethambutol and others.
Global Tuberculosis (TB) Therapeutics Market, by Disease Type 2018 (%)
Active TB to Hold a Major Share in the Global Tuberculosis (TB) Therapeutics Market
Amongst the disease type of the global market, active TB is projected to register significant growth during the forecast period. The segmental growth is accredited to the increased cases of active TB across the globe. In addition, growing incidence of DS (Drug-Sensitive)and MDR (Multidrug-resistant tuberculosis) TB cases due to incomplete or improper treatment may result in the disease which in turn creates scope for the market growth. As per the Centers for Disease Control and Prevention (CDC) in 2018, more than 9 million people are suffering from active TB per year across the globe. Increased focus of the key players to reduce and eliminate the disease by developing various drugs and novel treatment options is also projected to provide growth rate to the market growth during the forecast period.
Regional Outlook
Global tuberculosis (TB) therapeutics market is geographically segmented into North America, Europe, Asia-Pacific and the Rest of the World. North America is expected to hold a considerable share in global tuberculosis (TB) therapeutics market during the forecast period. This is attributed to the greatest number of cases recorded in the region. As per the CDC, more than 10,000 cases were recorded in the US alone in 2018. Along with this, peoples in the region are more concerned about health, which is further propelling the growth of the market in the region. Further, Asia-Pacific and is projected to register a significant CAGR over the forecast period.
Global Tuberculosis (TB) Therapeutics Market by Region, 2018 (%)
Key Players Outlook
Johnson and Johnson Services Inc., Lupin Ltd., Otsuka Pharmaceutical Co. Ltd., Macleods Pharmaceuticals Ltd., Merck & Co. Inc., Novartis International AG, and Pfizer Inc. among others are some of the key players operating in global tuberculosis therapeutics market. These companies are adopting several organic and inorganic growth strategies such as product launches & developments, partnerships, agreements, and acquisitions to strengthen their product portfolios and maintain a competitive position in global tuberculosis (TB) therapeutics market growth during the forecast period.
For instance, in October 2019, TB Alliance and Macleods Pharmaceuticals Ltd established a partnership for new therapy for highly drug-resistant TB. Non-profit drug developer TB Alliance has granted Macleods Pharmaceuticals a non-exclusive license for manufacturing the anti-TB drug pretomanid as part of the three-drug “BPaL” regimen. Pending regulatory approvals, Macleods has agreed to commercialize the anti-tuberculosis (TB) medicine in around 140 countries and territories.
The Report Covers
- Market value data analysis of 2018 and forecast to 2025.
- Annualized market revenues ($ million) for each market segment.
- Country-wise analysis of major geographical regions.
- Key companies operating in global tuberculosis (TB) therapeutics market. Based on the availability of data, information related to pipeline products, and relevant news is also available in the report.
- Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
- Analysis of market-entry and market expansion strategies.
- Competitive strategies by identifying ‘who-stands-where’ in the market.
1. Report Summary
1.1. Research Methods and Tools
1.2. Market Breakdown
1.2.1. By Segments
1.2.2. By Geography
2. Market Overview and Insights
2.1. Scope of the Report
2.2. Analyst Insight & Current Market Trends
2.2.1. Key Findings
2.2.2. Recommendations
2.2.3. Conclusion
2.3. Rules & Regulations
3. Competitive Landscape
3.1. Competitive Dashboard
3.2. Key Strategy Analysis
3.3. Key Company Analysis
3.3.1. Johnson & Johnson Services, Inc.
3.3.1.1. Overview
3.3.1.2. Financial Analysis
3.3.1.3. SWOT Analysis
3.3.1.4. Recent Developments
3.3.2. Novartis International AG
3.3.2.1. Overview
3.3.2.2. Financial Analysis
3.3.2.3. SWOT Analysis
3.3.2.4. Recent Developments
3.3.3. Otsuka Pharmaceutical Co., Ltd.
3.3.3.1. Overview
3.3.3.2. Financial Analysis
3.3.3.3. SWOT Analysis
3.3.3.4. Recent Developments
3.3.4. Pfizer Inc.
3.3.4.1. Overview
3.3.4.2. Financial Analysis
3.3.4.3. SWOT Analysis
3.3.4.4. Recent Developments
3.3.5. Lupin Ltd.
3.3.5.1. Overview
3.3.5.2. Financial Analysis
3.3.5.3. SWOT Analysis
3.3.5.4. Recent Developments
4. Market Determinants
4.1. Motivators
4.2. Restraints
4.3. Opportunities
5. Market Segmentation
5.1. Global Tuberculosis (TB) Therapeutics Market by Disease Type
5.1.1. Active TB
5.1.2. Latent TB
5.2. Global Tuberculosis (TB) Therapeutics Market by Therapy
5.2.1. First-Line Therapy
5.2.2. Second-Line Therapy
6. Regional Analysis
6.1. North America
6.1.1. United States
6.1.2. Canada
6.2. Europe
6.2.1. UK
6.2.2. Germany
6.2.3. Italy
6.2.4. Spain
6.2.5. France
6.2.6. Rest of Europe
6.3. Asia-Pacific
6.3.1. China
6.3.2. India
6.3.3. Japan
6.3.4. Rest of Asia-Pacific
6.4. Rest of the World
7. Company Profiles
7.1. Akorn Inc.
7.2. AstraZeneca Plc
7.3. Biochemical and Synthetic Products Pvt Ltd.
7.4. Eli Lilly & Co.
7.5. GlaxoSmithKline Plc
7.6. Johnson and Johnson Services Inc.
7.7. LabatecPharma SA
7.8. Lupin Ltd.
7.9. Macleods Pharmaceuticals Ltd.
7.10. Merck& Co. Inc.
7.11. Mylan N.V.
7.12. Novartis International AG
7.13. Otsuka Pharmaceutical Co. Ltd.
7.14. Pfizer Inc.
7.15. Sanofi SA
1. GLOBAL TUBERCULOSIS (TB) THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY DISEASE TYPE, 2018-2025 ($ MILLION)
2. GLOBAL ACTIVE TBTHERAPEUTICS MARKET RESEARCH AND ANALYSIS BY REGION, 2018-2025 ($ MILLION)
3. GLOBAL LATENT TBTHERAPEUTICS MARKET RESEARCH AND ANALYSIS BY REGION, 2018-2025 ($ MILLION)
4. GLOBAL TUBERCULOSIS (TB) THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY THERAPY, 2018-2025 ($ MILLION)
5. GLOBAL FIRST-LINE THERAPY OF TBMARKET RESEARCH AND ANALYSIS BY REGION, 2018-2025 ($ MILLION)
6. GLOBAL SECOND-LINE THERAPY OF TBMARKET RESEARCH AND ANALYSIS BY REGION, 2018-2025 ($ MILLION)
7. GLOBAL TUBERCULOSIS (TB) THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY GEOGRAPHY, 2018-2025 ($ MILLION)
8. NORTH AMERICAN TUBERCULOSIS (TB) THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2018-2025 ($ MILLION)
9. NORTH AMERICAN TUBERCULOSIS (TB) THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY DISEASE TYPE, 2018-2025 ($ MILLION)
10. NORTH AMERICAN TUBERCULOSIS (TB) THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY THERAPY, 2018-2025 ($ MILLION)
11. EUROPEAN TUBERCULOSIS (TB) THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2018-2025 ($ MILLION)
12. EUROPEAN TUBERCULOSIS (TB) THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY DISEASE TYPE, 2018-2025 ($ MILLION)
13. EUROPEAN TUBERCULOSIS (TB) THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY THERAPY, 2018-2025 ($ MILLION)
14. ASIA-PACIFIC TUBERCULOSIS (TB) THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2018-2025 ($ MILLION)
15. ASIA-PACIFIC TUBERCULOSIS (TB) THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY DISEASE TYPE, 2018-2025 ($ MILLION)
16. ASIA-PACIFIC TUBERCULOSIS (TB) THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY THERAPY, 2018-2025 ($ MILLION)
17. REST OF THE WORLD TUBERCULOSIS (TB) THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY DISEASE TYPE, 2018-2025 ($ MILLION)
18. REST OF THE WORLD TUBERCULOSIS (TB) THERAPEUTICS MARKET RESEARCH AND ANALYSIS BY THERAPY, 2018-2025 ($ MILLION)
1. GLOBAL TUBERCULOSIS (TB) THERAPEUTICS MARKET SHARE BY DISEASE TYPE, 2018 VS 2025 (%)
2. GLOBAL TUBERCULOSIS (TB) THERAPEUTICS MARKET SHARE BY THERAPY, 2018 VS 2025 (%)
3. GLOBAL TUBERCULOSIS (TB) THERAPEUTICS MARKET SHARE BY GEOGRAPHY, 2018 VS 2025 (%)
4. US TUBERCULOSIS (TB) THERAPEUTICS MARKET SIZE, 2018-2025 ($ MILLION)
5. CANADA TUBERCULOSIS (TB) THERAPEUTICS MARKET SIZE, 2018-2025 ($ MILLION)
6. UK TUBERCULOSIS (TB) THERAPEUTICS MARKET SIZE, 2018-2025 ($ MILLION)
7. FRANCE TUBERCULOSIS (TB) THERAPEUTICS MARKET SIZE, 2018-2025 ($ MILLION)
8. GERMANY TUBERCULOSIS (TB) THERAPEUTICS MARKET SIZE, 2018-2025 ($ MILLION)
9. ITALY TUBERCULOSIS (TB) THERAPEUTICS MARKET SIZE, 2018-2025 ($ MILLION)
10. SPAIN TUBERCULOSIS (TB) THERAPEUTICS MARKET SIZE, 2018-2025 ($ MILLION)
11. ROE TUBERCULOSIS (TB) THERAPEUTICS MARKET SIZE, 2018-2025 ($ MILLION)
12. INDIA TUBERCULOSIS (TB) THERAPEUTICS MARKET SIZE, 2018-2025 ($ MILLION)
13. CHINA TUBERCULOSIS (TB) THERAPEUTICS MARKET SIZE, 2018-2025 ($ MILLION)
14. JAPAN TUBERCULOSIS (TB) THERAPEUTICS MARKET SIZE, 2018-2025 ($ MILLION)
15. REST OF ASIA-PACIFIC TUBERCULOSIS (TB) THERAPEUTICS MARKET SIZE, 2018-2025 ($ MILLION)
16. REST OF THE WORLD TUBERCULOSIS (TB) THERAPEUTICS MARKET SIZE, 2018-2025 ($ MILLION)
